drugset

drugset / Trial / NCT00148018

Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma

NCT00148018 ↗

Phase 2 Terminated 37 enrolled University of Cologne German Hodgkin's Lymphoma Study Group · collab Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate wether bortezomib and dexamethasone are active in patients with relapsed Hodgkin's lymphoma.

Timeline

Start: 2005-03
Primary completion: —
Completion: —

Publications

Trelle S, Sezer O, Naumann R, Rummel M, Keller U, Engert A, Borchmann P. Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018). Haematologica. 2007 Apr;92(4):568-9. doi: 10.3324/haematol.10797.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bortezomib	Small molecule	—	—
Subject	Dexamethasone	Small molecule	—	—

Indications